Long-Term Efficacy of Intravitreal Pegcetacoplan from the GALE Open-Label Extension Study of the Phase 3 OAKS and DERBY Trials in Patients With Geographic Atrophy (RS 2023 GA) - Apellis Medical Hub

Long-Term Efficacy of Intravitreal Pegcetacoplan from the GALE Open-Label Extension Study of the Phase 3 OAKS and DERBY Trials in Patients With Geographic Atrophy

Share Via Email

Back to Conference Resources

GA Congress Presentations Retina Society 2023

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.